1,474 Shares in Glaukos Co. (NYSE:GKOS) Acquired by Zhang Financial LLC

Zhang Financial LLC bought a new stake in shares of Glaukos Co. (NYSE:GKOS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,474 shares of the medical instruments supplier’s stock, valued at approximately $221,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Envestnet Asset Management Inc. increased its position in shares of Glaukos by 3.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 67,936 shares of the medical instruments supplier’s stock valued at $8,040,000 after purchasing an additional 2,341 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Glaukos during the second quarter valued at $1,346,000. Brighton Jones LLC bought a new stake in shares of Glaukos in the 2nd quarter valued at approximately $208,000. Sei Investments Co. lifted its holdings in shares of Glaukos by 51.6% in the 2nd quarter. Sei Investments Co. now owns 108,546 shares of the medical instruments supplier’s stock worth $12,847,000 after acquiring an additional 36,933 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC purchased a new position in Glaukos during the 2nd quarter valued at $212,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Gilbert H. Kliman sold 10,000 shares of Glaukos stock in a transaction on Friday, December 20th. The stock was sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. The trade was a 23.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at $15,310,024.65. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,603 shares of company stock valued at $2,605,678. Company insiders own 6.40% of the company’s stock.

Glaukos Price Performance

Shares of NYSE GKOS opened at $156.60 on Tuesday. The stock’s 50-day moving average is $146.21 and its two-hundred day moving average is $133.86. The company has a market cap of $8.63 billion, a price-to-earnings ratio of -51.85 and a beta of 1.04. Glaukos Co. has a 1-year low of $83.90 and a 1-year high of $161.13. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.50) earnings per share. Analysts forecast that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GKOS has been the subject of several research reports. Wells Fargo & Company upped their price target on shares of Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Piper Sandler set a $140.00 price target on shares of Glaukos in a report on Thursday, October 17th. Morgan Stanley lowered Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research note on Monday, December 2nd. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and increased their target price for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. Finally, Stephens raised shares of Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and a consensus target price of $147.75.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.